Notoginsenoside R1 attenuates experimental inflammatory bowel disease via pregnane X receptor activations

Journal of Pharmacology and Experimental Therapeutics

Volumn 352, Issue 2, 2015, Pages 315-324

  Zhang, Jingjing ^a   Ding, Lili ^a   Wang, Baocan ^b   Ren, Gaiyan ^a   Sun, Aning ^a   Deng, Chao ^a   Wei, Xiaohui ^a   Mani, Sridhar ^c   Wang, Zhengtao ^a   Dou, Wei ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; CYTOCHROME P450 3A11; GAMMA INTERFERON; GLUCURONOSYLTRANSFERASE 1A1; I KAPPA B ALPHA; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 15; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1; MYELOPEROXIDASE; NOTOGINSENOSIDE R1; PLANT MEDICINAL PRODUCT; PREGNANE X RECEPTOR; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; GINSENOSIDE; PEROXIDASE; STEROID RECEPTOR; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DISEASE SEVERITY; DOWN REGULATION; EXPERIMENTAL INFLAMMATORY BOWEL DISEASE; FEMALE; GENE EXPRESSION; HT 29 CELL LINE; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; UPREGULATION; XENOBIOTIC METABOLISM; ANIMAL; C57BL MOUSE; COLON; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; COLON; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GINSENOSIDES; HT29 CELLS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-6; MICE, INBRED C57BL; NF-KAPPA B; PEROXIDASE; RECEPTORS, STEROID; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84919708991     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.218750     Document Type: Article

References (39)

1. Atreya I, Atreya R, and Neurath MF (2008) NF-kappaB in inflammatory bowel disease. J Intern Med 263:591-596.
2. Baumgart DC and Sandborn WJ (2007) Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369:1641-1657.
3. Cheng J, Shah YM, and Gonzalez FJ (2012) Pregnane X receptor as a target for treatment of inflammatory bowel disorders. Trends Pharmacol Sci 33:323-330.
4. Cheng J, Shah YM, Ma X, Pang X, Tanaka T, Kodama T, Krausz KW, and Gonzalez FJ (2010) Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther 335:32-41.
5. Dou W, Mukherjee S, Li H, Venkatesh M, Wang H, Kortagere S, Peleg A, Chilimuri SS, Wang ZT, and Feng Y, et al. (2012) Alleviation of gut inflammation by Cdx2/ Pxr pathway in a mouse model of chemical colitis. PLoS ONE 7:e36075.
6. Dou W, Zhang J, Ren G, Ding L, Sun A, Deng C, Wu X, Wei X, Mani S, and Wang Z (2014) Mangiferin attenuates the symptoms of dextran sulfate sodium-induced colitis in mice via NF-κB and MAPK signaling inactivation. Int Immunopharmacol 23 :170-178.
7. Dou W, Zhang J, Sun A, Zhang E, Ding L, Mukherjee S, Wei X, Chou G, Wang ZT, and Mani S (2013a) Protective effect of naringenin against experimental colitis via suppression of Toll-like receptor 4/NF-κB signalling. Br J Nutr 110:599-608.
8. Dou W, Zhang J, Zhang E, Sun A, Ding L, Chou G, Wang Z, and Mani S (2013b) Chrysin ameliorates chemically induced colitis in the mouse through modulation of a PXR/NF-κB signaling pathway. J Pharmacol Exp Ther 345:473-482.
9. Dring MM, Goulding CA, Trimble VI, Keegan D, Ryan AW, Brophy KM, Smyth CM, Keeling PW, O'Donoghue D, and O'Sullivan M, et al. (2006) The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 130:341-348, quiz 592.
10. Fan JS, Liu DN, Huang G, Xu ZZ, Jia Y, Zhang HG, Li XH, and He FT (2012) Panax notoginseng saponins attenuate atherosclerosis via reciprocal regulation of lipid metabolism and inflammation by inducing liver X receptor alpha expression. J Ethnopharmacol 142:732-738.
11. Geng J, Peng W, Huang Y, Fan H, and Li S (2010) Ginsenoside-Rg1 from Panax notoginseng prevents hepatic fibrosis induced by thioacetamide in rats. Eur J Pharmacol 634:162-169
12. Gilroy L and Allen PB (2014) Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease? Clin Exp Gastroenterol 7:163-172.
13. Gu X, Ke S, Liu D, Sheng T, Thomas PE, Rabson AB, Gallo MA, Xie W, and Tian Y (2006) Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J Biol Chem 281:17882-17889.
14. Gupta SC, Patchva S, and Aggarwal BB (2013) Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 15:195-218.
15. Jobin C (2010) Probiotics and ileitis: could augmentation of TNF/NFκB activity be the answer? Gut Microbes 1:196-199.
16. Langmann T, Moehle C, Mauerer R, Scharl M, Liebisch G, Zahn A, Stremmel W, and Schmitz G (2004) Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 127:26-40.
17. Liu X and Wang JM (2011) Iridoid glycosides fraction of Folium syringae leaves modulates NF-κB signal pathway and intestinal epithelial cells apoptosis in experimental colitis. PLoS ONE 6:e24740.
18. Mani S, Dou W, and Redinbo MR (2013) PXR antagonists and implication in drug metabolism. Drug Metab Rev 45:60-72.
19. Mencarelli A, Migliorati M, Barbanti M, Cipriani S, Palladino G, Distrutti E, Renga B, and Fiorucci S (2010) Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells. Biochem Pharmacol 80:1700-1707.
20. Meng X, Sun G, Ye J, Xu H, Wang H, and Sun X (2014) Notoginsenoside R1-mediated neuroprotection involves estrogen receptor-dependent crosstalk between Akt and ERK1/2 pathways: a novel mechanism of Nrf2/ARE signaling activation. Free Radic Res 48:445-460.
21. Neurath MF and Travis SP (2012) Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 61:1619-1635.
22. Nones K, Dommels YE, Martell S, Butts C, McNabb WC, Park ZA, Zhu S, Hedderley D, Barnett MP, and Roy NC (2009) The effects of dietary curcumin and rutin on colonic inflammation and gene expression in multidrug resistance gene-deficient (mdr1a-/-) mice, a model of inflammatory bowel diseases. Br J Nutr 101:169-181.
23. Shah YM, Ma X, Morimura K, Kim I, and Gonzalez FJ (2007) Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression. Am J Physiol Gastrointest Liver Physiol 292: G1114-G1122.
24. Shin EK, Kwon HS, Kim YH, Shin HK, and Kim JK (2009) Chrysin, a natural flavone, improves murine inflammatory bowel diseases. Biochem Biophys Res Commun 381:502-507.
25. Smutny T, Mani S, and Pavek P (2013) Post-translational and post-transcriptional modifications of pregnane X receptor (PXR) in regulation of the cytochrome P450 superfamily. Curr Drug Metab 14:1059-1069.
26. Sun K, Wang CS, Guo J, Horie Y, Fang SP, Wang F, Liu YY, Liu LY, Yang JY, and Fan JY, et al. (2007) Protective effects of ginsenoside Rb1, ginsenoside Rg1, and notoginsenoside R1 on lipopolysaccharide-induced microcirculatory disturbance in rat mesentery. Life Sci 81:509-518.
27. Sun B, Xiao J, Sun XB, and Wu Y (2013) Notoginsenoside R1 attenuates cardiac dysfunction in endotoxemic mice: an insight into oestrogen receptor activation and PI3K/Akt signalling. Br J Pharmacol 168:1758-1770.
28. Tak PP and Firestein GS (2001) NF-κB: a key role in inflammatory diseases. J Clin Invest 107:7-11.
29. Tolson AH and Wang H (2010) Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv Drug Deliv Rev 62:1238-1249.
30. van der Marel S, Majowicz A, van Deventer S, Petry H, Hommes DW, and Ferreira V (2011) Gene and cell therapy based treatment strategies for inflammatory bowel diseases. World J Gastrointest Pathophysiol 2:114-122.
31. Venkatesh M, Wang H, Cayer J, Leroux M, Salvail D, Das B, Wrobel JE, and Mani S (2011) In vivo and in vitro characterization of a first-in-class novel azole analog that targets pregnane X receptor activation. Mol Pharmacol 80:124-135.
32. Wahli W (2008) A gut feeling of the PXR, PPAR and NF-kappaB connection. J Intern Med 263:613-619.
33. Wang H, Li H, Moore LB, Johnson MD, Maglich JM, Goodwin B, Ittoop OR, Wisely B, Creech K, and Parks DJ, et al. (2008) The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor. Mol Endocrinol 22:838-857.
34. Wang CZ, Xie JT, Fishbein A, Aung HH, He H, Mehendale SR, He TC, Du W, and Yuan CS (2009) Antiproliferative effects of different plant parts of Panax notoginseng on SW480 human colorectal cancer cells. Phytother Res 23:6-13.
35. Wu TY, Khor TO, Saw CL, Loh SC, Chen AI, Lim SS, Park JH, Cai L, and Kong AN (2011) Anti-inflammatory/Anti-oxidative stress activities and differential regulation of Nrf2-mediated genes by non-polar fractions of tea Chrysanthemum zawadskii and licorice Glycyrrhiza uralensis. AAPS J 13:1-13.
36. Xie W and Tian Y (2006) Xenobiotic receptor meets NF-kappaB, a collision in the small bowel. Cell Metab 4:177-178.
37. Zhang J, Dou W, Zhang E, Sun A, Ding L, Wei X, Chou G, Mani S, and Wang Z (2014) Paeoniflorin abrogates DSS-induced colitis via a TLR4-dependent pathway. Am J Physiol Gastrointest Liver Physiol 306:G27-G36.
38. Zhang B, Xie W, and Krasowski MD (2008) PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 9 :1695-1709.
39. Zhou C, Tabb MM, Nelson EL, Grün F, Verma S, Sadatrafiei A, Lin M, Mallick S, Forman BM, and Thummel KE, et al. (2006) Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J Clin Invest 116:2280-2289.